U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07743632) titled 'Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC' on July 30.
Brief Summary: This study will test the effectiveness of two standard neoadjuvant chemotherapy regimens plus an investigational drug (ivonescimab) that has dual action as both immunotherapy and therapy targeting the tumor's blood supply. This investigational drug is called ivonescimab.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Triple Negative Breast Cancer
Intervention:
DRUG: Carboplatin
Commercially available
DRUG: Docetaxel
Commercially available
DRUG: Doxorubicin
Commercially available.
DRUG: C...